Research programme: effervescent formulation therapeutics - EffRx/Kadmon
Latest Information Update: 12 Jun 2014
At a glance
- Originator Kadmon Corporation
- Developer EffRx; Kadmon Corporation
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Hepatolenticular degeneration; Unspecified
Most Recent Events
- 12 Jun 2014 Early research in Wilson's disease in USA (unspecified route)
- 12 Jun 2014 Early research in Wilson's disease in Switzerland (unspecified route)
- 18 Mar 2014 Early research in Undefined indication in USA (unspecified route)